SETting Up for Epigenetic Regulation of Advanced Prostate Cancer
Phillip Thienger1, Mark A Rubin2
1Department for BioMedical Research, University of Bern, Switzerland.
Abstract:
An outgrowth of therapy-resistant prostate cancers (PCa) with enhanced metastatic potential may be triggered by inhibitors of androgen receptor (AR) signaling, often via epigenetic rewiring. In this issue of Cancer Cell, Yuan et al. demonstrate how SETD2 integrates EZH2 and AMPK signaling pathways to keep PCa metastasis in check.
Insights
Therapy-resistant prostate cancer (PCa) can become more metastatic due to androgen receptor (AR) signaling inhibitors. A new study shows SETD2 regulates EZH2 and AMPK pathways, controlling PCa metastasis.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Therapy-resistant prostate cancer (PCa) poses a significant clinical challenge.
- Inhibitors of androgen receptor (AR) signaling can paradoxically promote cancer metastasis through epigenetic alterations.
Purpose of the Study:
- To investigate the molecular mechanisms underlying the enhanced metastatic potential of therapy-resistant prostate cancer.
- To identify key regulators involved in epigenetic rewiring and metastasis.
Main Methods:
- The study by Yuan et al. focuses on the role of the enzyme SETD2.
- Investigated the integration of EZH2 and AMPK signaling pathways.
Main Results:
- SETD2 plays a crucial role in regulating the metastatic potential of prostate cancer.
- The integration of EZH2 and AMPK signaling by SETD2 is essential for controlling PCa metastasis.
Conclusions:
- SETD2 acts as a critical checkpoint against prostate cancer metastasis.
- Understanding SETD2's function offers potential therapeutic targets for advanced prostate cancer.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation


